breadcrumb separatorProgram for students

Welcome to the ARESTIN Student Access Program, 

ARESTIN Student Access is a program sponsored by OraPharma, the makers of ARESTIN (minocycline HCl) Microspheres, 1 mg, and designed with the help of dental educators. Once you have completed the ARESTIN Student Access Program, we hope you will have the knowledge to recognize appropriate patients with periodontal disease, convey the benefits of treatment and associated risks, and provide treatment that includes ARESTIN + scaling and root planing (SRP), when indicated.

What to expect

The ARESTIN Student Access Program is divided into 2 sections and is designed to complement your current periodontal coursework.

Jump to: ARESTIN 101 | ARESTIN 201

ARESTIN 101 Curriculum

ARESTIN 101 is an introduction to periodontal disease and treatment that includes ARESTIN + scaling and root planing (SRP). Clinician-patient communication is also highlighted in this section.

  • Classwork focuses on disease state, clinical efficacy, and safety data
  • Laboratory session focuses on proper placement of ARESTIN and communication techniques that can be used to explain periodontal disease and treatment options

ARESTIN 101 Student Reading

ARESTIN 201 Curriculum

ARESTIN 201 deals with the clinical use and application of ARESTIN with an emphasis on patient selection and case study development.

  • Classwork focuses on treatment planning
  • Clinical session focuses on periodontal patient case development and treatment with ARESTIN

ARESTIN 201 Student Reading

 

The ARESTIN Student Access Program is sponsored by OraPharma, a division of Bausch Health US, LLC.

 

Profile

Name:

Manage Profile

Error:

Help

Questions? Contact us at 1-866-273-7846 or studentaccess@orapharma.com.

The ARESTIN Student Access Program is sponsored by OraPharma, a division of Bausch Health US, LLC.

See More

IMPORTANT SAFETY INFORMATION AND INDICATION

  • ARESTIN® (minocycline HCl) is contraindicated in any patient who has a known sensitivity to minocycline or tetracyclines. Hypersensitivity reactions and hypersensitivity syndrome that included, but were not limited to anaphylaxis, anaphylactoid reaction, angioneurotic edema, urticaria, rash, eosinophilia, and one or more of the following: hepatitis, pneumonitis, nephritis, myocarditis, and pericarditis may be present. Swelling of the face, pruritus, fever and lymphadenopathy have been reported with the use of ARESTIN. Some of these reactions were serious. Post-marketing cases of anaphylaxis and serious skin reactions such as Stevens Johnson syndrome and erythema multiforme have been reported with oral minocycline, as well as acute photosensitivity reactions.
See Less

IMPORTANT SAFETY INFORMATION AND INDICATION

  • ARESTIN® (minocycline HCl) is contraindicated in any patient who has a known sensitivity to minocycline or tetracyclines. Hypersensitivity reactions and hypersensitivity syndrome that included, but were not limited to anaphylaxis, anaphylactoid reaction, angioneurotic edema, urticaria, rash, eosinophilia, and one or more of the following: hepatitis, pneumonitis, nephritis, myocarditis, and pericarditis may be present. Swelling of the face, pruritus, fever and lymphadenopathy have been reported with the use of ARESTIN. Some of these reactions were serious. Post-marketing cases of anaphylaxis and serious skin reactions such as Stevens Johnson syndrome and erythema multiforme have been reported with oral minocycline, as well as acute photosensitivity reactions.
  • THE USE OF DRUGS OF THE TETRACYCLINE CLASS DURING TOOTH DEVELOPMENT MAY CAUSE PERMANENT DISCOLORATION OF THE TEETH, AND THEREFORE SHOULD NOT BE USED IN CHILDREN OR IN PREGNANT OR NURSING WOMEN.
  • Tetracyclines, including oral minocycline, have been associated with development of autoimmune syndromes including a lupus-like syndrome manifested by arthralgia, myalgia, rash, and swelling. Sporadic cases of serum sickness-like reaction have presented shortly after oral minocycline use, manifested by fever, rash, arthralgia, lymphadenopathy and malaise. In symptomatic patients, diagnostic tests should be performed and ARESTIN treatment discontinued.
  • The use of ARESTIN in an acutely abscessed periodontal pocket or for use in the regeneration of alveolar bone has not been studied.
  • The safety and effectiveness of ARESTIN has not been established in immunocompromised patients or in those with coexistent oral candidiasis. Use with caution if there is a predisposition to oral candidiasis.
  • In clinical trials, the most frequently reported nondental treatment-emergent adverse events were headache, infection, flu syndrome, and pain.

To report SUSPECTED ADVERSE REACTIONS, contact Bausch Health US, LLC at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

INDICATION

ARESTIN® (minocycline HCl) Microspheres, 1mg is indicated as an adjunct to scaling and root planing (SRP) procedures for reduction of pocket depth in patients with adult periodontitis. ARESTIN® may be used as part of a periodontal maintenance program, which includes good oral hygiene and SRP.

Click here for full Prescribing Information.